Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A prospective multicenter intra-individual comparison trial. First line atezolizumab + ...
ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its ...
A newly developed MRI-based scoring system may help identify patients at higher risk of early recurrence after surgical removal of small hepatocellular carcinoma (HCC). The findings, published in ...
Quibim, a global company pioneering imaging biomarkers for precision medicine, is today announcing the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver diseases through ...
New findings from the DIRECT PLUS, 18-month-long lifestyle intervention trial underscores the potential to observe and signify alterations of MRI-assessed liver fat with proteomics according to new ...
A form of MRI technology can quantify liver response in patients with nonalcoholic steatohepatitis, according to recent research by the University of California San Diego School of Medicine. Here’s ...
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, ...
PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny minority of patients undergoing initial staging for hepatocellular carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results